misoprostol and Dermatitis--Atopic

In this blinded randomized placebo-controlled trial, 20 dogs with atopic dermatitis (AD) were given placebo (8 dogs) or misoprostol (12 dogs) at 5 micro g kg-1, orally, three times daily for 3 weeks. Administration of the active drug, but not of placebo, led to a significant decrease in lesional and pruritus scores. The median reduction from baseline of both scores was approximately 30%. Misoprostol therapy did not lead to decreases of dermal cell counts or skin tumour necrosis factor (TNF)alpha mRNA copy numbers that were significantly different from those of placebo. Skin TNFalpha protein production, assessed using indirect immunofluorescence, decreased or remained unchanged in dogs receiving misoprostol. In contrast, post treatment TNFalpha fluorescence scores were higher in all but two dogs given placebo. The changes from baseline of TNFalpha fluorescence scores did not correlate significantly with those of lesional or pruritus indices. These observations confirm the modest efficacy of misoprostol for treatment of canine AD and suggest that its mild anti-allergic effects are not associated with either inhibition of inflammatory cell emigration or TNFalpha production.. Résumé Dans cette étude randomisée en aveugle, 20 chiens présentant une dermatite atopique ont reçu un placebo (8 chiens) ou du misoprostol (12 chiens) à la posologie de 5 µg kg. Resumen En este ensayo ciego, al azar y controlado con placebo, a veinte perros con DA se les administró oralmente placebo (8 perros) o misoprostol (12 perros) a una dosis de 5 µg kg. Zusammenfassung In dieser randomisierten, plazebo-kontrollierten Doppelblindstudie wurden 20 Hunde mit atopischer Dermatitis (AD) entweder mit Plazebo (8 Hunde) oder mit 5 µg kg

Topics: Administration, Oral; Animals; Dermatitis, Atopic; Dermatologic Agents; Dog Diseases; Dogs; Double-Blind Method; Female; Fluorescent Antibody Technique, Indirect; Male; Misoprostol; RNA, Messenger; Treatment Outcome; Tumor Necrosis Factor-alpha